EXPRESSION OF MUTANT P53, C-ERBB-2 AND THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN TRANSITIONAL CELL-CARCINOMA OF THE HUMAN URINARY-BLADDER

被引:186
作者
WRIGHT, C
MELLON, K
JOHNSTON, P
LANE, DP
HARRIS, AL
HORNE, CHW
NEAL, DE
机构
[1] UNIV NEWCASTLE UPON TYNE,DEPT PATHOL,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND
[2] UNIV NEWCASTLE UPON TYNE,DEPT SURG UROL,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND
[3] JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND
[4] IMPERIAL CANC RES FUND,MOLEC IMMUNOCHEM LAB,POTTERS BAR,HERTS,ENGLAND
关键词
D O I
10.1038/bjc.1991.211
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Expression of the p53, the epidermal growth factor receptor (EGFr; c-erbB-1) and c-erbB-2 proteins was studied in 82 patients with primary transitional cell carcinoma of the bladder using an immuno-histochemical method. Strong or moderate staining was found in 18% of tumours for p53 with weaker staining in a further 36% giving a total of 54% of tumours stained for p53. Strong staining was found in 15% of tumours for c-erbB-2 and in 31% for the EGFr. Tumours invading the bladder muscle were significantly more likely to be strongly stained positively for p53 and/or EGFr compared with superficial tumours: only 15% of invasive tumours were stained negatively for both p53 and EGFr. No statistical association was found between p53 and EGFr expression. Weakly positive associations were found between the expression of c-erbB-2 and p53 and between muscle invasive tumours and increased expression of c-erbB-2. Alterations in the expression of p53, c-erbB-1 and c-erbB-2 were found frequently in human transitional cell carcinoma of the urinary bladder and may be of clinical use in defining patient sub-groups of differing prognosis.
引用
收藏
页码:967 / 970
页数:4
相关论文
共 41 条
  • [1] CHROMOSOME-17 DELETIONS AND P53 GENE-MUTATIONS IN COLORECTAL CARCINOMAS
    BAKER, SJ
    FEARON, ER
    NIGRO, JM
    HAMILTON, SR
    PREISINGER, AC
    JESSUP, JM
    VANTUINEN, P
    LEDBETTER, DH
    BARKER, DF
    NAKAMURA, Y
    WHITE, R
    VOGELSTEIN, B
    [J]. SCIENCE, 1989, 244 (4901) : 217 - 221
  • [2] BREAST-CANCER AND A PROTO-ONCOGENE
    BARNES, DM
    [J]. BRITISH MEDICAL JOURNAL, 1989, 299 (6707) : 1061 - 1062
  • [3] BARTEK J, 1990, ONCOGENE, V5, P893
  • [4] MOUSE P53 INHIBITS SV40 ORIGIN-DEPENDENT DNA-REPLICATION
    BRAITHWAITE, AW
    STURZBECHER, HW
    ADDISON, C
    PALMER, C
    RUDGE, K
    JENKINS, JR
    [J]. NATURE, 1987, 329 (6138) : 458 - 460
  • [5] P53 EXPRESSION IN BREAST-CANCER
    CATTORETTI, G
    RILKE, F
    ANDREOLA, S
    DAMATO, L
    DELIA, D
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1988, 41 (02) : 178 - 183
  • [6] NCL-CB11, A NEW MONOCLONAL-ANTIBODY RECOGNIZING THE INTERNAL DOMAIN OF THE C-ERBB-2 ONCOGENE PROTEIN EFFECTIVE FOR USE ON FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE
    CORBETT, IP
    HENRY, JA
    ANGUS, B
    WATCHORN, CJ
    WILKINSON, L
    HENNESSY, C
    GULLICK, WJ
    TUZI, NL
    MAY, FEB
    WESTLEY, BR
    HORNE, CHW
    [J]. JOURNAL OF PATHOLOGY, 1990, 161 (01) : 15 - 25
  • [7] THE P53 PROTO-ONCOGENE CAN ACT AS A SUPPRESSOR OF TRANSFORMATION
    FINLAY, CA
    HINDS, PW
    LEVINE, AJ
    [J]. CELL, 1989, 57 (07) : 1083 - 1093
  • [8] P53 AND DNA POLYMERASE-ALPHA COMPETE FOR BINDING TO SV40 T-ANTIGEN
    GANNON, JV
    LANE, DP
    [J]. NATURE, 1987, 329 (6138) : 456 - 458
  • [9] ACTIVATING MUTATIONS IN P53 PRODUCE A COMMON CONFORMATIONAL EFFECT - A MONOCLONAL-ANTIBODY SPECIFIC FOR THE MUTANT FORM
    GANNON, JV
    GREAVES, R
    IGGO, R
    LANE, DP
    [J]. EMBO JOURNAL, 1990, 9 (05) : 1595 - 1602
  • [10] GUSTERSON BA, 1988, MOL CELL PROBE, V2, P383